A drug cost analysis expert reveals that the life-saving drug Risdiplam, used to treat the rare genetic disease SMA, could ...

Roche’s Evrysdi (risdiplam) is the market leader among the drugs for spinal muscular atrophy (SMA). Biogen’s Spinraza ...

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a ...

Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug ...

Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.

Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...

Roche’s action in Delhi High Court seeking an injunction against Natco Pharma to prevent the introduction of a generic ...

NICE has rejected routine NHS funding for Roche's Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn't come as a surprise to patient association SMA UK.

CPCT provides free lifelong access to Risdiplam for 50 children with SMA, supported by Roche Pharma India and Karnataka government.

Roche, a Swiss multinational healthcare company, is seeking a permanent injunction against Natco Pharma to prevent the introduction of a generic version of Risdiplam, a Spinal Muscular Atrophy (SMA) ...

Health groups and patients calls for government interference to make rare disease drugs affordable: Our Bureau, New Delhi Tuesday, November 5, 2024, 18:10 Hrs [IST] Health groups ...